Reis-Filho JS - Search Results

1

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.

Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, Osborne CK, Schiff R. Veeraraghavan J, et al. Breast. 2017 Aug;34 Suppl 1(Suppl 1):S19-S26. doi: 10.1016/j.breast.2017.06.022. Epub 2017 Jul 4. Breast. 2017. PMID: 28687441 Free PMC article. Review.

2

The role of molecular analysis in breast cancer.

Geyer FC, Marchio C, Reis-Filho JS. Geyer FC, et al. Pathology. 2009 Jan;41(1):77-88. doi: 10.1080/00313020802563536. Pathology. 2009. PMID: 19089743 Review.

3

Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.

Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S. Resetkova E, et al. Breast Cancer Res Treat. 2010 Aug;123(1):97-108. doi: 10.1007/s10549-009-0619-3. Epub 2009 Nov 13. Breast Cancer Res Treat. 2010. PMID: 19911270

4

Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping.

Schwartz GF, Bartelink H, Burstein HJ, Cady B, Cataliotti L, Fentiman IS, Holland R, Hughes KS, Masood S, McCormick B, Palazzo JA, Pressman PI, Reis-Filho J, Pusztai L, Rutgers EJ, Seidman AD, Solin LJ, Sparano JA. Schwartz GF, et al. Breast J. 2012 Jul-Aug;18(4):303-11. doi: 10.1111/j.1524-4741.2012.01264.x. Breast J. 2012. PMID: 22759093

5

Activating mutations in HER2: neu opportunities and neu challenges.

Weigelt B, Reis-Filho JS. Weigelt B, et al. Cancer Discov. 2013 Feb;3(2):145-7. doi: 10.1158/2159-8290.CD-12-0585. Cancer Discov. 2013. PMID: 23400474

6

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.

Wetterskog D, Shiu KK, Chong I, Meijer T, Mackay A, Lambros M, Cunningham D, Reis-Filho JS, Lord CJ, Ashworth A. Wetterskog D, et al. Oncogene. 2014 Feb 20;33(8):966-76. doi: 10.1038/onc.2013.41. Epub 2013 Mar 11. Oncogene. 2014. PMID: 23474757

7

Tackling the diversity of triple-negative breast cancer.

Turner NC, Reis-Filho JS. Turner NC, et al. Clin Cancer Res. 2013 Dec 1;19(23):6380-8. doi: 10.1158/1078-0432.CCR-13-0915. Clin Cancer Res. 2013. PMID: 24298068 Review.

8

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.

Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J, Smith IE, Reis-Filho JS, Dowsett M. Arnedos M, et al. Ann Oncol. 2014 Mar;25(3):605-610. doi: 10.1093/annonc/mdt575. Epub 2014 Feb 12. Ann Oncol. 2014. PMID: 24525703 Free PMC article.

9

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.

Bidard FC, Ng CK, Cottu P, Piscuoglio S, Escalup L, Sakr RA, Reyal F, Mariani P, Lim R, Wang L, Norton L, Servois V, Sigal B, Vincent-Salomon A, Weigelt B, Pierga JY, Reis-Filho JS. Bidard FC, et al. Ann Oncol. 2015 Aug;26(8):1704-9. doi: 10.1093/annonc/mdv217. Epub 2015 May 7. Ann Oncol. 2015. PMID: 25953157 Free article.

10

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.

Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. Janiszewska M, et al. Nat Genet. 2015 Oct;47(10):1212-9. doi: 10.1038/ng.3391. Epub 2015 Aug 24. Nat Genet. 2015. PMID: 26301495 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

644 results

Search Page